CVAC News and Press, CureVac N.V. From 01/09/23

Dr. Franz-Werner Haas to complete successful tenure as CEO by March 31, 2023 Dr. Alexander Zehnder to succeed Dr. Haas as new CEO, joining from Sanofi on April 1, 2023 TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / January 9, 2023 / CureVac N.V. (NASDAQ:CVAC), a global biopha...

Following a ~29% gain in the previous session, German biotech CureVac N.V. ( NASDAQ: CVAC ) climbed another ~27% pre-market Monday as Wall Street welcomed the early Phase 1 data for the mRNA-based COVID-19 and flu shots the company develops with GSK ( GSK ). About ~445.7K Cure...

German biotech CureVac N.V. ( NASDAQ: CVAC ) closed ~29% higher on Friday, recording its biggest intraday gain ever after posting interim Phase 1 data for modified-mRNA-based COVID-19 and flu vaccine candidates the company co-develops with GSK ( NYSE: GSK ). The company sa...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Amid a strong showing on Wall Street prior to the weekend, shares of CureVac (NASDAQ: CVAC ) stock popped dramatically northward on positive data for its coronavirus and flu vaccines . Preliminary clinical results demonstr...

Promising COVID-19 and flu modified mRNA vaccine candidates identified based on positive preliminary data from ongoing Phase 1 studies All candidates use CureVac's advanced second-generation mRNA backbone optimized to achieve improved mRNA translation and strong immune responses at low doses...

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / December 14, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that Chief Executive Officer Franz-Werner Haas,...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . For further details see: Wall Street Breakfast: Shifting Gears

Summary The CureVac lags behind the US biotech sector, which has been on an upward trend since October. CureVac N.V. seems to have run out of fuel after giving it all during the pandemic crisis. CureVac N.V. shares currently seem to have no real chance of recovering from these level...

The following slide deck was published by CureVac N.V. in conjunction with their 2022 Q3 earnings call. For further details see: CureVac N.V. 2022 Q3 - Results - Earnings Call Presentation

Start Time: 09:00 End Time: 10:01 CureVac N.V. (CVAC) Q3 2022 Earnings Conference Call November 16, 2022, 09:00 AM ET Company Participants Franz-Werner Haas - CEO Pierre Kemula - CFO Ulrike Gnad-Vogt - Interim Chief Development Officer Ronald Plasterk...